Chewy's Positive Narrative Clashes with Valuation and Insider Overhang

What happened

A recent Zacks article highlights Chewy's market share gains driven by health and customer loyalty, with Autoship penetration at 83.9% and Vet Care expansion. However, the DeepValue report reveals that these strengths are already priced into a lofty valuation (P/E 51x) and overshadowed by significant insider selling, including a 10% owner fully exiting and the CTO's planned sales through 2026. Q3 FY2025 metrics were solid—sales up 8.3% YoY, adjusted EBITDA margin of 5.8%, and free cash flow of $175.8M—yet the stock has repeatedly fallen on beats, signaling market skepticism. The core thesis depends on continued gross margin expansion via structural drivers like sponsored ads, but competitive threats from Amazon and Walmart persist. The next critical catalyst is FY2026 guidance on March 25, 2026, which must reaffirm margin expansion to justify the current multiple.

Implication

The article reinforces Chewy's operational strengths but does not alter the risk/reward. With a P/E over 50x, the stock already discounts continued margin expansion. Insider selling, including a 10% owner exit, creates sentiment overhang that could cap upside. The real catalyst is March 25 guidance; if margins expand further, the stock may re-rate, but any miss could trigger sharp de-rating given limited safety. Caution is warranted—remain on the sidelines until the guidance provides clearer direction.

Thesis delta

The article reiterates the known narrative of market share gains via health and loyalty, but the DeepValue report confirms this is fully priced in and offset by insider selling. No fundamental shift has occurred; the risk/reward remains balanced with downside risk if gross margin improvement stalls. The thesis stays neutral-to-cautious until the March 2026 earnings event.